Heart failure (HF) is a common disease with high morbidity and mortality; however, none of the
drugs available are now entirely optimal for the treatment of HF. In addition to various clinical diseases and
environment influences, genetic factors also contribute to the development and progression of HF. Identifying
the common variants for HF by genome-wide association studies will facilitate the understanding of
pathophysiological mechanisms underlying HF. This review summarizes the recently identified common
variants for HF risk and outcome and discusses their implications for the clinic therapy.
Keywords: Common variants, Dilated cardiomyopathy, Genome-wide association studies, Heart failure, Mortality, Risk.
Rights & PermissionsPrintExport